Employees Retirement System of Texas Acquires New Shares in Edwards Lifesciences Corporation $EW

Employees Retirement System of Texas bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 69,100 shares of the medical research company’s stock, valued at approximately $5,404,000.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $266,000. Avantax Advisory Services Inc. lifted its stake in Edwards Lifesciences by 10.7% in the 1st quarter. Avantax Advisory Services Inc. now owns 10,707 shares of the medical research company’s stock worth $776,000 after purchasing an additional 1,032 shares in the last quarter. LPL Financial LLC increased its holdings in shares of Edwards Lifesciences by 23.9% in the first quarter. LPL Financial LLC now owns 324,351 shares of the medical research company’s stock worth $23,509,000 after purchasing an additional 62,671 shares during the period. Prosperity Consulting Group LLC raised its position in shares of Edwards Lifesciences by 6.8% in the first quarter. Prosperity Consulting Group LLC now owns 4,172 shares of the medical research company’s stock worth $302,000 after buying an additional 266 shares in the last quarter. Finally, N.E.W. Advisory Services LLC bought a new stake in Edwards Lifesciences during the first quarter valued at $50,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $86.78 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.40. The company has a fifty day moving average of $79.44 and a 200-day moving average of $78.31. The stock has a market capitalization of $50.36 billion, a price-to-earnings ratio of 12.49, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the company earned $0.67 EPS. The firm’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Sanford C. Bernstein reissued a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Robert W. Baird set a $83.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 31st. Finally, Citigroup lifted their target price on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.39.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.